1442-9071/asset/olbannerleft.gif?v=1&s=864b2676ecbb7b79a3b4729351f79b750283a00b)
1442-9071/asset/olbannerright.gif?v=1&s=2ba103739f1538f232a2b55c70e97e41430e4116)
Pneumococcal keratitis: a clinical profile
Article first published online: 12 FEB 2003
DOI: 10.1046/j.1442-9071.2003.00598.x
1442-9071/asset/cover.gif?v=1&s=7c6769e05691a4581ae173da02433f6f6fe197f7 "Clinical & Experimental Ophthalmology")
Additional Information
How to Cite
Parmar, P., Salman, A., Kalavathy, C. M., Jesudasan, C. N. and Thomas, P. A. (2003), Pneumococcal keratitis: a clinical profile. Clinical & Experimental Ophthalmology, 31: 44–47. doi: 10.1046/j.1442-9071.2003.00598.x
Publication History
- Issue published online: 12 FEB 2003
- Article first published online: 12 FEB 2003
- Abstract
- Article
- References
- Cited By
Keywords:
- chronic dacryocystitis;
- ciprofloxacin;
- infectious keratitis;
- Streptococcus pneumoniae
Abstract
Aim: To study the clinical features of pneumococcal keratitis and response to ciprofloxacin therapy.
Methods: A retrospective analysis was undertaken of 58 patients with culture-proven pneumococcal keratitis seen over a period of 2 years.
Results: Pneumococcal keratitis accounted for 33.3% of bacterial keratitis. Most cases presented with non-severe keratitis (77.5%). Co-existing sac pathology was more frequent in pneumococcal ulcers as compared to non-pneumococcal bacterial ulcers (50%vs 9%, P < 0.001). Characteristic clinical features enabling an accurate clinical diagnosis were found in 27.5% and lanceolate diplococci on Gram's stain were identified in 76% of cases. In vitro testing showed a high susceptibility to cephazolin and ciprofloxacin. All patients received ciprofloxacin as first-line therapy. Eighty per cent responded well with complete healing of the ulcer. A second drug was required in 8.5%.
Conclusion: Ciprofloxacin therapy can be effective in the treatment of pneumococcal keratitis.